NasdaqGM:VERABiotechs
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy
Why the FDA’s priority review for atacicept matters for Vera Therapeutics
Vera Therapeutics (VERA) shares are reacting to news that the U.S. FDA accepted the Biologics License Application for atacicept in IgA nephropathy for Priority Review, with a PDUFA target action date of July 7, 2026.
See our latest analysis for Vera Therapeutics.
The FDA’s Priority Review comes on the back of strong clinical data for atacicept and arrives after a sharp 59.45% 90 day share price return, while the 3 year...